A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation.
D000085:Acetates / Q000008:administration & dosage; D000588:Amines; D000927:Anticonvulsants / Q000008:administration & dosage; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003024:Clozapine / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids; D004363:Drug Utilization; D000077206:Gabapentin; D006801:Humans; D019338:Polypharmacy; D018967:Risperidone / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000191:economics; D014635:Valproic Acid / Q000008:administration & dosage; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D014150:Antipsychotic Agents; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D000077206:Gabapentin; D003024:Clozapine; D018967:Risperidone